Consistent with our clinical findings, SLC1A5 knockdown resulted in increased sensitivity to tamoxifen in luminal breast cancer cells, suggesting that high SLC1A5 expression might play a crucial role in therapeutic response to endocrine treatment. Here, SLC1A5 is linked to breast carcinoma.